公开(公告)号：US09278951B2

公开(公告)日：2016-03-08

申请号：US14114324

申请日：2012-04-30

Applicant: Wiley Youngs ,  Matthew Panzner ,  Claire Tessier ,  Michael Deblock ,  Brian Wright ,  Patrick Wagers ,  Nikki Robishaw

Inventor： Wiley Youngs ,  Matthew Panzner ,  Claire Tessier ,  Michael Deblock ,  Brian Wright ,  Patrick Wagers ,  Nikki Robishaw

IPC: C07D235/02 ,  C07D235/04 ,  C07D233/58 ,  C07D233/60 ,  C07D233/68 ,  C07D401/14 ,  C07D403/12 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D405/06 ,  C07D487/04 ,  C07D403/14 ,  C07D473/08

CPC classification number: C07D401/14 ,  C07D233/58 ,  C07D233/60 ,  C07D233/68 ,  C07D235/02 ,  C07D235/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/06 ,  C07D473/08 ,  C07D487/04

Abstract: Singly and multiply charged imidazolium cations (ICs) have been identified as a class of chemical compositions that possess potent antineoplastic, antibacterial and antimicrobial properties. The imidazolium cations disclosed demonstrate greater or equivalent potency towards cancerous cells as the current clinical standard, cisplatin. These imidazolium cations, however, achieve this efficacy without any of the known toxic side effects caused by heavy metal-based antineoplastic drugs such as cisplatin.

Abstract translation: 已经将单加和多倍荷电咪唑阳离子（IC）鉴定为具有有效的抗肿瘤，抗细菌和抗微生物特性的一类化学组合物。 所公开的咪唑阳离子表现出对目前临床标准顺铂的癌细胞更大或等效的效力。 然而，这些咪唑阳离子实现了这种功效，而没有由重金属基抗肿瘤药物如顺铂引起的任何已知的毒副作用。

公开(公告)号：US20140142307A1

公开(公告)日：2014-05-22

申请号：US14114324

申请日：2012-04-30

Applicant: Wiley Youngs ,  Matthew Panzner ,  Claire Tessier ,  Michael Deblock ,  Brian Wright ,  Patrick Wagers ,  Nikki Robishaw

Inventor： Wiley Youngs ,  Matthew Panzner ,  Claire Tessier ,  Michael Deblock ,  Brian Wright ,  Patrick Wagers ,  Nikki Robishaw

IPC: C07D487/04 ,  C07D233/58 ,  C07D401/06 ,  C07D403/14 ,  C07D401/14 ,  C07D473/08 ,  C07D235/02 ,  C07D233/68 ,  C07D405/06

CPC classification number: C07D401/14 ,  C07D233/58 ,  C07D233/60 ,  C07D233/68 ,  C07D235/02 ,  C07D235/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/06 ,  C07D473/08 ,  C07D487/04

Abstract: Singly and multiply charged imidazolium cations (ICs) have been identified as a class of chemical compositions that possess potent antineoplastic, antibacterial and antimicrobial properties. The imidazolium cations disclosed demonstrate greater or equivalent potency towards cancerous cells as the current clinical standard, cisplatin. These imidazolium cations, however, achieve this efficacy without any of the known toxic side effects caused by heavy metal-based antineoplastic drugs such as cisplati.

Abstract translation: 已经将单加和多倍荷电咪唑阳离子（IC）鉴定为具有有效的抗肿瘤，抗细菌和抗微生物特性的一类化学组合物。 所公开的咪唑阳离子表现出对目前临床标准顺铂的癌细胞更大或等效的效力。 然而，这些咪唑阳离子实现了这种功效，而没有由重金属基抗肿瘤药物如顺铂引起的任何已知的毒副作用。